Akèy › Kansè Metastatik › Kentucky › Lexington
Etid klinik pou Kansè Metastatik nan Lexington, KY
11 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Lexington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
- University of Kentucky/Markey Cancer Center, Lexington
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Ap rekriteFaz 1
- University of Kentucky/Markey Cancer Center, Lexington
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Ap rekriteFaz 2/3
- University of Kentucky Markey Cancer Center, Lexington
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Baptist Health Lexington, Lexington
- Baptist Health Richmond, Lexington
- Baptist Health Hamburg, Lexington
- ak 3 plis
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Ap rekriteFaz 2/3
- University of Kentucky Research Foundation, Lexington
- University of Kentucky Healthcare - Markey Cancer Center, Lexington
- University of Kentucky Medical Center, Lexington
- ak 1 plis
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Baptist Health Lexington, Lexington
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- CHI Saint Joseph Cancer Center - East, Lexington
- University of Kentucky Chandler Medical Center, Lexington
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Ap rekriteFaz 2
- University of Kentucky/Markey Cancer Center, Lexington
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Ap rekriteFaz 1/2
- Crinetics Study Site, Lexington
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Ap rekriteFaz 1
- UK Markey Cancer Center, Lexington
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- University of Kentucky Markey Cancer Center, Lexington
Etid Kansè Metastatik nan lòt vil
- Houston, TX104 etid
- New York City, NY93 etid
- Nashville, TN70 etid
- Boston, MA63 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- Chicago, IL45 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
Lòt etid nan Lexington
- Kansè Poumon ki pa ti selil23 etid
- Kansè poumon18 etid
- Kansè ovè16 etid
- Kansè pwostat14 etid
- Kansè (tout kalite)14 etid
- Kansè nan tete14 etid
- Kansè kolorektal11 etid
- Ensifizyans kadyak11 etid
- Melanom10 etid
- Leksemi mieloïd egi10 etid
- Obèsite10 etid
- Karsinòm selil skuamèz tèt ak kou9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.